$165.31−2.09 (−1.25%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Neurocrine Biosciences (NBIX) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Jun 30, 2026*. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 787 filers, Jun 30, 2026
# 13F FUNDS
787
13F VALUE
$17.2B
101.8M shares
Withheld: the 13F filers report more shares than the company has outstanding, which happens when shared or lent shares are counted twice. The filer count, shares and value are as filed.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | ROBERTS EIRY | Chief Medical Officer | Acquired · Grant / award | 8,314Stock Option | — | ↗ |
| Nov 4, 2026 | ROBERTS EIRY | Chief Medical Officer | Acquired · Grant / award | 1,506Restricted Stock Unit | — | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Acquired · Option exercise | 7,200 | $53.64 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 100 | $158.18 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 100 | $162.05 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 600 | $163.71 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 1,226 | $164.74 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 908 | $165.71 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 1,466 | $166.77 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 1,500 | $167.72 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 1,300 | $168.53 | ↗ |
| Nov 3, 2026 | MORROW GEORGE J | director | Disposed · Option exercise | 7,200Non-Qualified Stock Option | — | ↗ |
| Nov 2, 2026 | MORROW GEORGE J | director | Acquired · Option exercise | 7,500 | $53.64 | ↗ |
| Nov 2, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 1,900 | $144.98 | ↗ |
| Nov 2, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 4,300 | $145.86 | ↗ |
| Nov 2, 2026 | MORROW GEORGE J | director | Disposed · Open-market sale | 1,300 | $146.76 | ↗ |
| Nov 2, 2026 | MORROW GEORGE J | director | Disposed · Option exercise | 7,500Non-Qualified Stock Option | — | ↗ |
| Nov 1, 2026 | Gano Kyle | Chief Executive Officer | Acquired · Option exercise | 614 | — | ↗ |
| Nov 1, 2026 | Gano Kyle | Chief Executive Officer | Disposed · Tax withholding | 332 | $146.10 | ↗ |
| Nov 1, 2026 | Gano Kyle | Chief Executive Officer | Disposed · Option exercise | 614Restricted Stock Unit | — | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold Neurocrine Biosciences?
Neurocrine Biosciences was held by 787 13F filers as of Jun 30, 2026.
Not investment advice.

